Brazikumab
Pharmaceutical drug
- none
- 1610353-18-8
- none
- 50EI9G8Q6U
- D10912
Brazikumab (INN; development code MEDI2070) is a human monoclonal antibody designed for the treatment of Crohn's disease.[1][2] that targets IL-23.[3]
This drug was developed by MedImmune.
References
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Brazikumab, American Medical Association
- ^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
- ^ Hanžel J, D'Haens GR (April 2020). "Anti-interleukin-23 agents for the treatment of ulcerative colitis". Expert Opinion on Biological Therapy. 20 (4): 399–406. doi:10.1080/14712598.2020.1697227. PMID 31760827.
- v
- t
- e
Monoclonal antibodies for the immune system
| Human | |
|---|---|
| Humanized | |
| Veterinary |
| Mouse |
|
|---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
